Erasca, Inc. (ERAS)
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Erasca, Inc.
NASDAQ:ERASHealthcare · Biotechnology
-4.21%$14.35
AH$14.20-1.05%vs close
Mkt Cap$5.02B
Float254.49M
O/S349.76M
Vol
$ Vol
RVOL
Inst Own81.2%
SI14.5%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$124.55M
Total Assets$396.15M
Free Cash Flow-$95.58M
Debt & Equity
Debt 13%
Equity 87%
Total Debt$47.14M
Total Equity$325.17M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in ERAS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$396.15M
Liabilities$70.98M
Accounts Receivable$2.5M
Accounts Payable$981K
Inventory$0
PP&E (Net)$42.33M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $3.11M | $0 | $3.73M | $2.64M | $829K | $0 | $0 |
| Gross Profit | -$3.11M | $0 | -$3.73M | -$2.64M | -$829K | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $92.85M | $115.36M | $103.82M | $112.46M | $73.92M | $101.3M | $9.62M |
| Selling, General, and Administrative | $38.55M | $41.73M | $37.7M | $32.99M | $22.62M | $7.96M | $3.68M |
| Other | -$3.11M | $22.5M | -$3.73M | $99.36M | $27.52M | $0 | $0 |
| Total Operating Expenses | $128.3M | $179.59M | $137.79M | $244.81M | $124.05M | $109.25M | $13.29M |
| Operating Income (EBIT) | -$131.41M | -$179.59M | -$141.53M | -$247.45M | -$124.88M | -$109.25M | -$13.29M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $201.36M | $0 | $0 | $0 |
| Interest Income | $16.61M | $20.09M | $16.71M | $4.9M | $190K | $336K | $1.3M |
| Other Income (Expense) | $6.86M | $17.94M | $16.48M | $4.64M | $2.12M | $7.59M | $1.25M |
| Income Before Tax (EBT) | -$124.55M | -$161.65M | -$125.04M | -$242.81M | -$122.76M | -$101.66M | -$12.04M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$124.55M | -$161.65M | -$125.04M | -$242.81M | -$122.76M | -$101.66M | -$12.04M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| Diluted EPS | -0.44 | -0.69 | -0.83 | -1.99 | -1.03 | -0.85 | -0.10 |
| Weighted Average OS | 283.53M | 233.82M | 150.18M | 122.02M | 119.10M | 118.96M | 118.96M |
| EBITDA | -$121.44M | -$153.28M | -$121.31M | -$240.16M | -$121.94M | -$36.97M | -$12.98M |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $73.81M | $67.74M | $93.08M | $284.22M | $360.49M | $65.38M | $29.58M |
| Short-Term Investments | $202.27M | $230.57M | $219.28M | $151.4M | $53.99M | $53.33M | $20.79M |
| Cash and Short-Term Investments | $276.07M | $298.31M | $312.35M | $435.62M | $414.48M | $118.7M | $50.37M |
| Accounts Receivable | $2.5M | $2.3M | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $7.66M | $8.18M | $1.1M | $748K | $100K | $1.29M | $0 |
| Total Current Assets | $286.24M | $308.79M | $320.68M | $444.5M | $420.02M | $119.99M | $51.12M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $42.33M | $48.54M | $60.19M | $65.23M | $33.31M | $4.07M | $4.33M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $66.13M | $142.16M | $10.05M | $2M | $44.77M | $312K | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.45M | $3.03M | $4.38M | $3.18M | $3.32M | $451K | $56K |
| Total Long-Term Assets | $109.92M | $193.73M | $74.62M | $70.41M | $81.4M | $4.83M | $4.39M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $396.15M | $502.53M | $395.3M | $514.91M | $501.42M | $124.83M | $55.51M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $981K | $468K | $2M | $23.05M | $4.68M | $878K | $1.38M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $877K | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $12.07M | $10.65M | $10.78M | $2.33M | $4.16M | $9.51M | $447K |
| Total Current Liabilities | $28.51M | $31.39M | $26.16M | $48.69M | $26.22M | $13.68M | $2.75M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $399K | $362K | $566K | $573K | $158K | $1.61M | $63.4M |
| Total Long-Term Liabilities | $42.47M | $47.63M | $52.45M | $54.37M | $18.66M | $3.72M | $66.37M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $70.98M | $79.03M | $78.61M | $103.06M | $44.89M | $17.4M | $69.12M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $221.41M | $63.4M |
| Common Stock | $28K | $28K | $15K | $15K | $12K | $3K | $3K |
| Retained Earnings | -$892.21M | -$767.66M | -$606.01M | -$480.97M | -$238.17M | -$115.4M | -$13.74M |
| Comprehensive Income & Other | $628K | $405K | $77K | -$1.04M | -$162K | $2K | $11K |
| Other Stockholders' Equity | $1.22B | $1.19B | $922.68M | $892.81M | $694.68M | $222.82M | $135K |
| Total Equity | $325.17M | $423.5M | $316.69M | $411.85M | $456.53M | $107.42M | -$13.6M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $396.15M | $502.53M | $395.3M | $514.91M | $501.42M | $124.83M | $55.51M |
| Supplementary Data | |||||||
| Total Debt | $47.14M | $51.89M | $55.86M | $55.1M | $18.79M | $2.99M | $3.69M |
| Net Debt | -$26.67M | -$15.85M | -$37.22M | -$229.12M | -$341.7M | -$62.39M | -$25.89M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$124.55M | -$161.65M | -$125.04M | -$242.81M | -$122.76M | -$101.66M | -$12.04M |
| Depreciation & Amortization | $3.11M | $3.81M | $3.73M | $2.64M | $829K | $540K | $310K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$1.51M | $0 | $0 |
| Stock-Based Compensation | $24.9M | $26.97M | $26.23M | $20.11M | $8.33M | $797K | $122K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $513K | -$1.53M | -$886K | $676K | $1.34M | -$380K | $1.17M |
| Other Working Capital | -$3.84M | $3.27M | $1.7M | $15.11M | $6.36M | $3.67M | $541K |
| Total Working Capital Change | -$3.33M | $1.74M | $813K | $15.79M | $7.71M | $3.29M | $1.71M |
| Other Non-Cash Items | $4.41M | $19.72M | -$6.95M | $101.01M | $27.81M | $64.35M | -$483K |
| Net Cash from Operating | -$95.45M | -$109.42M | -$101.22M | -$103.26M | -$79.6M | -$32.69M | -$10.38M |
| Investing Activities | |||||||
| Capital Expenditures | -$128K | -$60K | -$1.77M | -$16.55M | -$18.89M | -$947K | -$597K |
| Acquisitions | $0 | $0 | $0 | $4M | $7.68M | $0 | $0 |
| Purchases of Investments | -$150.97M | -$403.38M | -$314.39M | -$134.33M | -$105.81M | -$99.2M | -$58.89M |
| Sales of Investments | $261.03M | $269.32M | $244.94M | $79.8M | $60.11M | $66.69M | $38.6M |
| Other Investing Activities | -$9.5M | -$22.5M | -$20M | -$4M | -$7.68M | -$37.74M | $0 |
| Net Cash from Investing | $100.42M | -$156.62M | -$91.22M | -$71.08M | -$64.59M | -$71.2M | -$20.89M |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $1.1M | $239.06M | $1.29M | $95.25M | $317M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $1.64M | $0 | $2.82M | $3M | $3.02M | $0 |
| Net Cash from Financing | $1.1M | $240.7M | $1.29M | $98.08M | $439.4M | $139.99M | $16.86M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.07M | -$25.34M | -$191.14M | -$76.27M | $295.21M | $36.1M | -$14.4M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$95.45M | -$109.42M | -$101.22M | -$103.26M | -$79.6M | -$32.69M | -$10.38M |
| Capital Expenditure | -$128K | -$22.56M | -$1.77M | -$16.55M | -$18.89M | -$38.69M | -$597K |
| Free Cash Flow | -$95.58M | -$131.98M | -$102.99M | -$119.81M | -$98.48M | -$71.38M | -$10.97M |
| Cash at Beginning | $68.15M | $93.48M | $284.63M | $360.89M | $65.69M | $29.58M | $43.98M |
| Cash at End | $74.21M | $68.15M | $93.48M | $284.63M | $360.89M | $65.69M | $29.58M |